Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3?years

G. L.-H. Wong; V. W.-S. Wong; H.-Y. Chan; P. C.-H. Tse; J. Wong; A. M.-L. Chim; K. K.-L. Yiu; S. H.-T. Chu; H. L.-Y. Chan

首页> 外文期刊>Alimentary Pharmacology & Therapeutics >Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3?years

【24h】

Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3?years

机译：恩替卡韦治疗第12个月未检测到HBV DNA预测，慢性乙型肝炎患者3年后仍可保持病毒抑制和HBeAg血清转化

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

On-treatment monitoring of serum hepatitis B virus (HBV) DNA to guide treatment strategy for patients on entecavir has received little attention.

机译：恩替卡韦治疗期间监测血清乙型肝炎病毒（HBV）DNA以指导患者的治疗策略受到关注。

著录项

来源
《Alimentary Pharmacology & Therapeutics》 |2012年第11期|1326-1335|共10页
作者
G. L.-H. Wong; V. W.-S. Wong; H.-Y. Chan; P. C.-H. Tse; J. Wong; A. M.-L. Chim; K. K.-L. Yiu; S. H.-T. Chu; H. L.-Y. Chan;
展开▼
作者单位

Institute of Digestive Disease The Chinese University of Hong Kong Hong Kong SAR China;

Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong SAR China;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years [J] . WongG.L.-H., WongV.W.-S., ChanH.-Y., Alimentary pharmacology & therapeutics. . 2012,第11期

机译：恩替卡韦治疗第12个月未检测到HBV DNA预测，慢性乙型肝炎患者3年后仍可保持病毒抑制和HBeAg血清转化
2. HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients [J] . Cheng-Yuan Peng, Tsung-Cheng Hsieh, Tsai-Yuan Hsieh, Journal of the Formosan Medical Association =: Taiwan yi zhi . 2015,第4期

机译：6个月的HBV-DNA水平在6个月的Entecavir治疗中预测HBeAg阳性慢性乙型肝炎患者的HBEAG损失
3. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA [J] . GaoL., TrinhH.N., LiJ., Alimentary pharmacology & therapeutics. . 2014,第6期

机译：在具有高HBV DNA的HBeAg阳性慢性乙型肝炎患者中，替诺福韦优于恩替卡韦具有完全的病毒抑制作用
4. Negative Effect of IFN-onα2b against HBV-DNA in PBMC, Serum and Inducement to CD25 in the Patients with Chronic Hepatitis B [C] . WANG Jian, SUN Lin, XIANG Gui-ju, 2009 IEEE International Symposium on IT in Medicine Education( IEEE 教育与医药信息化国际会议）论文集 . 2009

机译：慢性乙型肝炎患者IFN-α2b对PBMC HBV-DNA，血清和CD25诱导的负面影响
5. Viral Vaccine Vectors for the Treatment of Chronic Hepatitis B Virus Infection. [D] . Reynolds, Tracy Dawn. 2015

机译：用于治疗慢性乙型肝炎病毒感染的病毒疫苗载体。
6. Tenofovir is superior to entecavir for achieving complete viral suppression in hbeag-positive chronic hepatitis b patients with high hbv dna [O] . Linyi Gao, Huy N. Trinh, Jiayi Li, -1

机译：替诺福韦优于恩替卡韦在高HBV dna的HBeag阳性慢性乙型肝炎患者中实现完全的病毒抑制
7. Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years [O] . Xi Zhang, Xiaocui An, Lei Shi, 2021

机译：基线定量HBCAB强烈预测慢性乙型肝炎患者10年治疗的慢性乙型肝炎患者中未检测到的HBV DNA和RNA

Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3?years

摘要

著录项

相似文献

相关主题

期刊订阅